Immune cells from your own tumor: a new hope for advanced cancer?

NCT ID NCT05430373

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a personalized treatment called GT101 for adults with advanced solid tumors that have spread or come back. Doctors take immune cells from the patient's own tumor, grow them in a lab, and infuse them back after mild chemotherapy. The goal is to see if this approach is safe and can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR RECURRENT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS, ADULT

Contacts and locations

Locations

Chongqing University Cancer Center
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 201321, China
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
RECRUITING

Beijing, Beijing Municipality, 100039, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China
West China School of Medicine/West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610064, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.